Stelara (Ustekinumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Description

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two key proteins involved in inflammatory and autoimmune responses. It is commonly used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for stelara (Ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and other conditions. Plaque psoriasis is a chronic autoimmune disorder that leads to the rapid buildup of skin cells, creating scaly, inflamed patches, often on the scalp, elbows, and knees. Stelara can be administered via subcutaneous injection or intravenous infusion and is available through various distribution channels, including hospital, retail, and online pharmacies. It is used for pediatric, adult, and geriatric patients.

The stelara (ustekinumab) market research report is one of a series of new reports from The Business Research Company that provides stelara (ustekinumab) market statistics, including stelara (ustekinumab) industry global market size, regional shares, competitors with a stelara (ustekinumab) market share, detailed stelara (ustekinumab) market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. This stelara (ustekinumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $14,768.5 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to expanding indications for stelara, increasing prevalence of autoimmune diseases, high efficacy in refractory cases compared to alternatives, rising awareness among patients and healthcare providers, growing focus on personalized medicine. Major trends in the forecast period include adoption of biologic therapies, development of advanced drug delivery systems, data-driven healthcare systems, partnerships and licensing agreements between pharmaceutical companies, advances in biologics manufacturing technologies.

The growing prevalence of psoriasis is expected to drive the growth of the stelara (ustekinumab) market in the future. Psoriasis patients are individuals dealing with a chronic autoimmune disorder that speeds up skin cell turnover, resulting in red, scaly patches. The rise in psoriasis prevalence can be attributed to factors such as better diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, which helps psoriasis patients by effectively reducing inflammation and plaque formation. This leads to improved skin clearance and long-term symptom management, ultimately enhancing patients' quality of life. For instance, in May 2024, a report from the National Library of Medicine, a U.S.-based medical library, revealed that in 2022, psoriasis prevalence increased to 0.221%, with 6,930 cases of PsA reported in a population of 3,133,500. As a result, the rising prevalence of psoriasis patients is expected to fuel the growth of the stelara (ustekinumab) market.

A key trend in the stelara (ustekinumab) market is the development of innovative products, such as Stelara biosimilars, which offer a cost-effective treatment option for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications designed to replicate the therapeutic effects of Stelara (Ustekinumab), targeting IL-12 and IL-23 to treat autoimmune diseases like psoriasis and psoriatic arthritis. For example, in October 2024, Accord BioPharma Inc., a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab). IMULDOSA is notable for its broad indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. It is also uniquely indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it versatile across different age groups. This wide range of indications positions IMULDOSA as a valuable treatment for various immune-mediated inflammatory diseases.

In December 2023, Lotus Pharmaceutical, a Taiwan-based pharmaceutical company, partnered with Favorex Pte Ltd. to introduce a biosimilar of ustekinumab to the South Korean market. With this collaboration, Lotus Pharmaceutical aims to leverage Favorex Pte Ltd.'s expertise and market presence to bring a cost-effective biosimilar of ustekinumab to South Korea, addressing the demand for affordable biologic therapies while expanding its presence in the region's pharmaceutical sector. Favorex Pte Ltd. is a pharmaceutical company based in Singapore.

The Key player operating in the stelara (ustekinumab) market is Johnson & Johnson.

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stelara (ustekinumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the stelara (ustekinumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stelara (Ustekinumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stelara (ustekinumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for stelara (ustekinumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The stelara (ustekinumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric
Companies Mentioned: Johnson & Johnson
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33122

1. Executive Summary

2. Stelara (Ustekinumab) Market Characteristics

3. Stelara (Ustekinumab) Market Biologic Drug Characteristics

3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy

4. Stelara (Ustekinumab) Market Trends And Strategies

5. Stelara (Ustekinumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Stelara (Ustekinumab) Growth Analysis And Strategic Analysis Framework

6.1. Global Stelara (Ustekinumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Stelara (Ustekinumab) Market Growth Rate Analysis
6.4. Global Stelara (Ustekinumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Stelara (Ustekinumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Stelara (Ustekinumab) Total Addressable Market (TAM)

7. Global Stelara (Ustekinumab) Market Pricing Analysis & Forecasts

8. Stelara (Ustekinumab) Market Segmentation

8.1. Global Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plaque Psoriasis
Psoriatic Arthritis
Crohn's Disease
Ulcerative Colitis
Other Indications
8.2. Global Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous Injection
Intravenous Infusion
8.3. Global Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
8.4. Global Stelara (Ustekinumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric

9. Global Stelara (Ustekinumab) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications

10. Stelara (Ustekinumab) Market Regional And Country Analysis

10.1. Global Stelara (Ustekinumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Stelara (Ustekinumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Stelara (Ustekinumab) Market

11.1. Asia-Pacific Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Stelara (Ustekinumab) Market

12.1. China Stelara (Ustekinumab) Market Overview
12.2. China Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Stelara (Ustekinumab) Market

13.1. India Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Stelara (Ustekinumab) Market

14.1. Japan Stelara (Ustekinumab) Market Overview
14.2. Japan Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Stelara (Ustekinumab) Market

15.1. Australia Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Stelara (Ustekinumab) Market

16.1. South Korea Stelara (Ustekinumab) Market Overview
16.2. South Korea Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Stelara (Ustekinumab) Market

17.1. Western Europe Stelara (Ustekinumab) Market Overview
17.2. Western Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Stelara (Ustekinumab) Market

18.1. UK Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Stelara (Ustekinumab) Market

19.1. Germany Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Stelara (Ustekinumab) Market

20.1. France Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Stelara (Ustekinumab) Market

21.1. Eastern Europe Stelara (Ustekinumab) Market Overview
21.2. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Stelara (Ustekinumab) Market

22.1. North America Stelara (Ustekinumab) Market Overview
22.2. North America Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Stelara (Ustekinumab) Market

23.1. USA Stelara (Ustekinumab) Market Overview
23.2. USA Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Stelara (Ustekinumab) Market

24.1. Canada Stelara (Ustekinumab) Market Overview
24.2. Canada Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Stelara (Ustekinumab) Market

25.1. South America Stelara (Ustekinumab) Market Overview
25.2. South America Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Stelara (Ustekinumab) Market

26.1. Middle East Stelara (Ustekinumab) Market Overview
26.2. Middle East Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Stelara (Ustekinumab) Market

27.1. Africa Stelara (Ustekinumab) Market Overview
27.2. Africa Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Stelara (Ustekinumab) Market Competitive Landscape And Company Profiles

28.1. Stelara (Ustekinumab) Market Competitive Landscape
28.2. Stelara (Ustekinumab) Market Company Profiles
- 28.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

29. Global Stelara (Ustekinumab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Stelara (Ustekinumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Stelara (Ustekinumab) Market

32. Recent Developments In The Stelara (Ustekinumab) Market

33. Stelara (Ustekinumab) Market High Potential Countries, Segments and Strategies

33.1 Stelara (Ustekinumab) Market In 2029 - Countries Offering Most New Opportunities
33.2 Stelara (Ustekinumab) Market In 2029 - Segments Offering Most New Opportunities
33.3 Stelara (Ustekinumab) Market In 2029 - Growth Strategies
- 33.3.1 Market Trend Based Strategies
- 33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. The Business Research Company
34.6. Copyright And Disclaimer